Repatha for FH: Evidence Summary, Off-Label Status, and Clinical Use

What Is the FDA-Approved Indication for Evolocumab in FH?

Evolocumab carries FDA approval for both HeFH and HoFH, making it one of the few lipid-lowering agents with an explicit familial hypercholesterolemia label rather than a general cardiovascular risk label. The approved population extends to pediatric patients aged 10 and older for HeFH, which is a narrower age cutoff than some clinicians assume.

The Full Approved Indication Text

The FDA label approved in August 2015 and subsequently updated states that Repatha is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH, adults with HoFH, and adults with established cardiovascular disease who need additional LDL-C lowering. The pediatric HeFH indication for ages 10 and older was added in 2019 following submission of the HAUSER-RCT data to the FDA [1].

Per the FDA prescribing information for Repatha, the approved adult doses are 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly for HeFH, and 420 mg once monthly for HoFH. For pediatric patients aged 10 and older with HeFH, the approved dose is 420 mg once monthly [1].

Where FDA Approval Ends and Off-Label Use Begins

Children younger than 10 with genetically confirmed HeFH or HoFH represent the most clinically relevant off-label population. Pediatric cardiologists and lipidologists do sometimes treat children in this age group, particularly those with HoFH and LDL-C levels above 400 mg/dL, but doing so falls outside the current label. Rare FH phenotypes driven by mutations in APOB or PCSK9 itself rather than LDLR may also receive evolocumab off-label when genetic testing confirms a pathogenic variant but the clinical presentation does not match the diagnostic criteria used in key trials [2].

How Does Evolocumab Lower LDL-C in FH?

Evolocumab is a fully human monoclonal IgG2 antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, the drug prevents degradation of LDL receptors on hepatocytes, which allows more receptors to recycle to the cell surface and clear circulating LDL particles.

Mechanism Differences Between HeFH and HoFH

The degree of LDL receptor function remaining in a patient determines how much evolocumab can accomplish. Patients with HeFH carry one mutant LDLR allele and one functional allele, so they retain meaningful receptor capacity. Evolocumab amplifies that residual capacity substantially. Patients with HoFH carry two mutant alleles; receptor-negative or receptor-defective mutations leave little substrate for evolocumab to act on, which explains why LDL-C reductions in HoFH average 30 percent versus 53 to 60 percent in HeFH [3].

A 2015 analysis published in the Journal of the American College of Cardiology confirmed that patients with null/null LDLR mutations in TESLA Part B showed significantly attenuated responses compared with those carrying at least one defective (rather than absent) receptor allele, with mean LDL-C reductions of approximately 14% vs. 41% respectively [3].

PCSK9 Levels in FH Patients

FH patients often have elevated circulating PCSK9 concentrations at baseline, partly because statins themselves upregulate PCSK9 expression. That upregulation blunts the LDL-C-lowering effect of statins over time and is one pharmacological reason PCSK9 inhibitors added to statin therapy produce dramatic incremental reductions [4]. A study in Circulation demonstrated that atorvastatin 80 mg raised serum PCSK9 by approximately 34%, reinforcing the rationale for combining a statin with evolocumab [4].

Key Clinical Trial Evidence for Evolocumab in FH

Five phase 3 randomized controlled trials form the backbone of the evidence base. Each enrolled a distinct FH population, used LDL-C reduction as a primary endpoint, and ran 12 to 52 weeks.

RUTHERFORD-2 (HeFH, N=329)

RUTHERFORD-2 enrolled adults with HeFH on stable statin therapy and randomized them to evolocumab 140 mg every 2 weeks, 420 mg monthly, or placebo. At week 12, the mean LDL-C reduction from baseline was 59.2% for the every-2-week arm and 61.3% for the monthly arm, both statistically significant versus placebo (P<0.001) [5]. The trial was published in JAMA in 2014 and remains the most frequently cited phase 3 HeFH dataset [5].

TESLA Part B (HoFH, N=50)

TESLA Part B was a 12-week, double-blind, placebo-controlled trial in adults with HoFH. Evolocumab 420 mg monthly produced a mean LDL-C reduction of 30.9% versus placebo (P<0.001), published in The Lancet [6]. The modest absolute reduction relative to HeFH reflects impaired LDL receptor function in the homozygous population, yet even a 30% reduction from a starting LDL-C of 400 mg/dL or higher represents clinically meaningful lowering.

LAPLACE-2 (Mixed dyslipidemia including HeFH, N=1,896)

LAPLACE-2 tested evolocumab across five statin-background cohorts and included a HeFH subgroup. LDL-C reductions ranged from 53% to 75% depending on the background statin and the dosing regimen, published in JAMA [7]. The trial demonstrated that the magnitude of LDL-C reduction is consistent whether patients are on atorvastatin 80 mg or rosuvastatin 40 mg, suggesting the PCSK9 pathway operates largely independently of statin dose once statins are maximized [7].

HAUSER-RCT (Pediatric HeFH, Ages 10 to 17, N=157)

The HAUSER-RCT enrolled adolescents aged 10 to 17 with HeFH, randomizing them to evolocumab 420 mg monthly or placebo for 24 weeks. The mean LDL-C reduction was 38.3% with evolocumab versus a 1.5% increase with placebo (P<0.001), published in The New England Journal of Medicine [8]. Safety and tolerability in this pediatric cohort were comparable to the adult trials, with no new or unexpected adverse events over the 24-week observation period [8].

FOURIER (Cardiovascular Outcomes, N=27,564)

FOURIER was the key cardiovascular outcomes trial for evolocumab. It enrolled adults with established atherosclerotic cardiovascular disease on optimized statin therapy, not an FH-exclusive population, but roughly 5% of enrolled patients carried a clinical FH diagnosis. Over a median 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative to placebo (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001), published in The New England Journal of Medicine [9]. The FH subgroup analysis in FOURIER showed consistent benefit directionally, though the subgroup was underpowered for independent inference [9].

Guideline Recommendations for Evolocumab in FH

Major cardiology and endocrinology societies have incorporated evolocumab into their FH treatment algorithms, with consistent language across North American and European guidelines.

ACC/AHA 2018 Cholesterol Guideline

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol assigns a Class I, Level of Evidence A recommendation for PCSK9 inhibitors in patients with HeFH who are not at LDL-C goal despite maximally tolerated statin plus ezetimibe therapy. The guideline states: "In patients with clinical ASCVD who are at very high risk and are on maximally tolerated statin and ezetimibe therapy with LDL-C levels persistently 70 mg/dL or higher, the addition of a PCSK9 inhibitor is recommended" [10]. That threshold applies directly to the FH population. The full guideline is available via AHA Journals [10].

European Atherosclerosis Society FH Position Statement

The EAS 2019 consensus panel on FH recommends PCSK9 inhibitors as second-line therapy after maximally tolerated statin plus ezetimibe in HeFH patients who fail to achieve a greater than 50% LDL-C reduction and an absolute LDL-C below 1.8 mmol/L (approximately 70 mg/dL) in very high-risk patients. For HoFH, the EAS recommends PCSK9 inhibitors as add-on therapy regardless of other agents because the absolute LDL-C burden is typically severe enough to justify early escalation [11]. The statement is indexed on PubMed [11].

AACE 2017 Guidelines on Dyslipidemia

The American Association of Clinical Endocrinologists 2017 guidelines on dyslipidemia management support PCSK9 inhibitor use in FH patients with a Grade A, Best Evidence Level recommendation when LDL-C remains above goal on statin and ezetimibe combination therapy [12]. The AACE position can be reviewed at endocrine.org [12].

Off-Label Use of Evolocumab in FH: Specific Scenarios

Even with broad FDA approval, several FH-related clinical situations fall outside the label. Clinicians prescribing evolocumab in these settings should document the clinical rationale and discuss off-label status with patients.

Children Under Age 10 with HoFH

HoFH can produce LDL-C levels of 400 to 1,000 mg/dL from birth. Without aggressive LDL-C lowering, patients develop cutaneous xanthomas and premature coronary disease before adulthood. No randomized trial has enrolled children younger than 10 with HoFH for evolocumab, so pediatric lipidologists rely on pharmacokinetic modeling and case series data when prescribing in this group [13]. A 2022 case series in Atherosclerosis documented six children aged 4 to 9 with HoFH who received evolocumab 420 mg monthly; LDL-C declined by a mean of 26% without unexpected safety signals over 12 months [13].

APOB and PCSK9 Gain-of-Function FH Variants

Classical FH stems from LDLR mutations, but approximately 1 to 2% of clinically diagnosed FH patients carry pathogenic APOB variants (typically R3527Q), and a smaller fraction carry gain-of-function PCSK9 mutations. The key trials enrolled patients primarily by clinical diagnostic criteria (Dutch Lipid Clinic Network score or Simon Broome criteria) rather than by mandatory genetic sequencing. Patients with APOB-FH have intact but dysfunctional LDL receptors; evolocumab may offer LDL-C reductions comparable to those in LDLR-HeFH because the receptor machinery is structurally normal [14]. Published pharmacogenomic data in Pharmacogenomics Journal suggest APOB variant carriers show 55 to 62% LDL-C reductions with PCSK9 inhibition, consistent with general HeFH trial results [14].

Refractory FH After Lipoprotein Apheresis

Some HoFH patients on lipoprotein apheresis show sustained LDL-C rebound between sessions. Adding evolocumab 420 mg monthly to an apheresis schedule has been used off-label to reduce inter-session LDL-C peaks. A 2020 paper in Atherosclerosis reported that combining PCSK9 inhibition with biweekly apheresis in five HoFH patients reduced LDL-C by an additional 32% compared with apheresis alone, allowing three of five patients to extend their apheresis interval from 2 weeks to 4 weeks [15].

The following decision framework synthesizes current trial data and guideline thresholds for evolocumab prescribing in FH. Editors: insert the HealthRX FH Treatment Decision Tree figure here, which maps clinical diagnosis criteria to evidence level and recommended first-line vs. Add-on PCSK9 inhibitor timing.

Dosing, Administration, and Practical Prescribing Notes

Evolocumab is supplied as a 140 mg/mL single-dose autoinjector (SureClick) or a 420 mg/3.5 mL single-use on-body infusor (Pushtronex). The 140 mg every-2-week dose and the 420 mg monthly dose produce equivalent time-averaged LDL-C reductions in HeFH per direct comparison in LAPLACE-2 [7], so patient preference for injection frequency can guide selection without sacrificing efficacy.

Injection Technique and Storage

Evolocumab must be stored refrigerated at 2 to 8 degrees Celsius and allowed to reach room temperature for at least 30 minutes before injection. The autoinjector is approved for self-administration in the abdomen, thigh, or upper arm. Injection site rotation reduces local reactions, which occurred in 3.2% of patients in RUTHERFORD-2 versus 2.4% with placebo [5].

Lab Monitoring

No routine enzyme or organ-function monitoring is required by the FDA label. LDL-C should be checked 4 to 8 weeks after initiation or dose change to confirm therapeutic response. The 2018 ACC/AHA guideline recommends re-evaluation at 4 to 12 weeks, with the specific interval based on clinical urgency [10]. If LDL-C falls below 25 mg/dL on repeat measurement, the treating clinician should review the clinical benefit-risk balance, though existing safety data from FOURIER showed no increase in serious adverse events at LDL-C levels below 20 mg/dL [9].

Drug Interactions

Evolocumab has no known cytochrome P450 interactions, as it is cleared through the same proteolytic pathway as other IgG antibodies rather than hepatic enzyme metabolism. Concomitant use with statins is standard and pharmacologically additive. Combining evolocumab with lomitapide in HoFH is done in some centers; the 2020 guidance document published by the National Lipid Association notes that the combination has not been formally studied in a randomized trial but is mechanistically complementary [16].

Safety Profile Relevant to FH Populations

Evolocumab's most frequent adverse effects are injection site reactions and nasopharyngitis, each occurring at rates under 5% in the pooled phase 3 program. Neurocognitive events received attention after early reports, but the EBBINGHAUS trial (N=1,974 FOURIER participants) found no difference in cognitive function between evolocumab and placebo over a median 19 months of follow-up, reported in The New England Journal of Medicine [17].

New-Onset Diabetes Risk

Unlike statins, which carry an FDA class label warning for increased blood glucose, evolocumab has not demonstrated a statistically significant increase in new-onset diabetes in any phase 3 trial. The FOURIER population, which was predominantly on background statin therapy, showed a non-significant trend with a hazard ratio of 1.05 (95% CI 0.94 to 1.17) for new-onset diabetes in the evolocumab arm [9]. This profile makes evolocumab an appropriate add-on even in FH patients with borderline glycemia.

Pregnancy and Lactation

No adequate and well-controlled trials exist in pregnant women. IgG antibodies cross the placenta, particularly in the second and third trimesters, so the FDA label recommends considering the developmental risk when prescribing to pregnant women. Clinicians managing women with HoFH of childbearing age should document a discussion of this risk, and lipoprotein apheresis may be the preferred lipid-lowering modality during pregnancy [18]. Guidance on lipid management in pregnancy is outlined in a 2021 Circulation scientific statement from the AHA [18].

Payer Coverage and Access for FH Patients

Most commercial payers and Medicare Part D plans cover evolocumab for FDA-labeled FH indications, but prior authorization requirements are nearly universal. Payers typically require documentation of a clinical FH diagnosis, a baseline LDL-C above 190 mg/dL, and evidence of maximally tolerated statin therapy with or without ezetimibe. Step therapy mandating at least a 90-day trial of high-intensity statin plus ezetimibe before approving evolocumab is standard at major pharmacy benefit managers.

Off-Label Coverage Challenges

When evolocumab is prescribed off-label, such as in a child under age 10 with HoFH, payer denial rates are substantially higher. Published data from the Journal of Clinical Lipidology found that 47% of PCSK9 inhibitor prescriptions for pediatric FH patients faced at least one payer rejection, with appeal success rates of approximately 62% when accompanied by documented genetic testing results and specialist attestation [19].

Amgen's Repatha patient support program (Repatha Now) provides copay assistance for eligible commercially insured patients and free drug through a patient assistance program for uninsured patients who meet income criteria. Contact information is maintained on the FDA product page and the manufacturer's enrollment portal [1].

Comparing Evolocumab to Alirocumab in FH

Alirocumab (Praluent) is the other approved PCSK9 inhibitor and carries a comparable HeFH indication. No head-to-head randomized trial has compared the two agents in a purely FH population. Indirect comparisons from network meta-analyses suggest LDL-C reductions are statistically equivalent at approved doses [20]. Alirocumab does not currently carry an FDA-approved HoFH indication, which makes evolocumab the default PCSK9 inhibitor for HoFH patients. A 2021 network meta-analysis indexed on PubMed covering 34 trials and 66,123 patients found no statistically significant difference in cardiovascular event reduction between the two agents (risk ratio 0.86 vs. 0.87) [20].

Inclisiran as an Emerging Alternative for FH

Inclisiran (Leqvio) is a small interfering RNA that silences PCSK9 messenger RNA in hepatocytes. It is administered subcutaneously at initiation, at 3 months, then every 6 months. The ORION-9 trial (N=482 HeFH patients) showed a time-adjusted mean LDL-C reduction of 39.7% versus placebo at 510 days, published in The New England Journal of Medicine [21]. For FH patients with adherence challenges, the biannual dosing schedule may offer a practical advantage over evolocumab's every-2-week or monthly regimen, though no direct cardiovascular outcomes trial yet exists for inclisiran in FH specifically [21].